SELLAS Life Sciences to Present at Two Upcoming February Investor Conferences

- BIO CEO & Investor Conference on February 13 -
- RBC Capital Markets Healthcare Conference on February 21 -

NEW YORK, Feb. 06, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the following upcoming conferences.

• BIO CEO & Investor Conference 2018
  Date: Tuesday, February 13, 2018
  Presentation Time: 2:30 PM ET
  Location: New York Marriott Marquis, New York, NY

• 2018 RBC Capital Markets Healthcare Conference
  Date: Wednesday, February 21, 2018
  Presentation Time: 2:35 PM ET
  Location: Lotte New York Palace Hotel, New York, NY

A live webcast of each presentation can be accessed on the investor page of SELLAS’ website at www.sellaslifesciences.com/investors.  A replay of each webcast will also be archived for up to 30 days on SELLAS’ website following the conference.  

About SELLAS Life Sciences Group

SELLAS Life Sciences Group is a development-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic cancers and solid tumor indications. GPS is Phase 3-ready for two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM), and is also in development as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS recently received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]

David Moser, JD
Sellas Life Sciences Group
813-864-2571
[email protected]

Source: SELLAS Life Sciences Group, Inc.